Important Dates:
EORTC Brain Cancer Group: Glasgow, UK; October 16, 2024
Alliance Fall Meeting (Hybrid): Chicago, IL; October 30-November 1, 2024
NRG Winter Meeting: Phoenix, AZ; January 16-18, 2025
Alliance Spring Meeting (Hybrid): Chicago, IL; April 30-May 3, 2025
NRG Summer Meeting: Washington, DC; July 24-26, 2025
In the spring report, we highlighted the Alliance trial “A071401, Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations.”
In this report, we highlight the NRG trial BN003 “Phase III trial of observation versus irradiation for a gross totally resected grade II meningioma.” The aim of the study is to compare the clinical outcomes (progression free survival) of adjuvant RT versus observation for patients with newly diagnosed grade 2 meningiomas who undergo gross total resection. Patients are randomized to receive RT versus observation. Secondary outcomes include overall survival, neurocognitive function and patient reported outcomes. Accrual is ongoing. Target enrollment is 163 patients. PI is Leland Rogers, MD.
For additional information on joining these meetings or workgroups, please visit the following links or reach out to the following contacts:
NRG:
Webpage: https://www.nrgoncology.org/Meetings
Contact: meeting-reg@nrgoncology.org
Alliance:
Contact: Meetings@AllianceNCTN.org
EORTC:
Webpage: https://www.eortc.org/event/eortc-brain-tumour-group-autumn-meeting-3/
Contact: events@eortc.org
QOD-Tumor Registry
The current price point is a three-year contract at $5,000/year plus funding of a 0.5 FTE for data entry. Patient accrual and startup of interested neurosurgical groups has increased steadily since the Tumor QOD opened.
A total of 13 centers are actively enrolling patients with an additional seven centers in contract. The registry includes outcomes from 129 neurosurgeons and more than 4,621 patients, of which 2,870 patients have three-month follow-up including quality of life metrics. The registry has newly formed a Committee for Outcomes Research (CORe), which will initiate new retrospective and prospective studies among active centers.
Those interested in more information regarding participating in the QOD-Tumor Registry should contact Brad Elder at brad.elder@osumc.edu, Raj Mukherjee at drraj@jhmi.edu or Michele Anderson at manderson@neuropoint.org